Short answer
Definium Therapeutics, Inc. (DFTX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$159M
- −271.9% YoY · −106.2% QoQ
- EPS (diluted)
- −$1.44
- −213.0% YoY · −102.8% QoQ
Source: XBRL data from the Definium Therapeutics, Inc. (DFTX) Q2 2026 10-Q on SEC EDGAR. USD.
Definium Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product candidates commercialized
- Net loss $159.0M vs $42.7M YoY; operating loss $75.1M vs $40.9M
- Highest R&D spending DT120 GAD $22.6M; DT402 lowest at $0.4M
- Cash, equivalents and investments approximately $1.1B; June offering net proceeds $757.9M
- Cash runway into 2030; Voyage and Panorama readouts anticipated August and September 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Definium Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.